ArticleFrontiers in public health2025
Estimating the costs and quality of life impact of vision loss in the population aged 50-80 years in Malta: evidence from The Malta Eye Study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visual impairment and related ocular conditions impose substantial direct, indirect, and intangible costs, encompassing healthcare expenses, productivity losses, and reduced quality of life. Despite the global relevance of visual impairment, no comprehensive cost analysis has yet been conducted in an older adult Maltese population aged 50-80 years. Methods: Prevalence estimates from the population-based Malta Eye Study were used to calculate indirect costs via the gross national income per capita method with disability weight assumptions. Direct medical costs for key ocular conditions, including refractive error, cataract, age-related macular degeneration, diabetic retinopathy, and glaucoma, were estimated using prevalence, hospital, and private data performance indices and relevant cost data, enabling estimation of service coverage and unmet care needs. Intangible costs were derived from quality-of-life measures using the National Eye Institute Visual Function Questionnaire-39 to calculate disability weights and years lived with disability (YLD). Results: The productivity losses from blindness and moderate-severe visual impairment among individuals aged 50-80 were estimated at €16.0 million per annum (95% CI €6.0-€43.0 million). The estimated annual direct medical costs from the main ocular causes were estimated to sum up to €53.4 million (95% CI €44.6-€67.0 million), with unmet needs amounting to €20.8 million (95% CI €15.5-€28.5 million). Cataract (56.9%) and refractive error (24.5%) accounted for the highest shares of such costs. Vision-related quality of life correlated with the severity and laterality of visual impairment. Mild unilateral visual impairment carried the highest YLD rate 2264.4 YLDs per 100,000 while uncorrected refractive error carried the highest YLD rate among the visually impairing causes (2452.7 YLDs per 100,000). Discussion: Visual impairment imposes a considerable economic and quality-of-life burden on an older adult population in Malta, driven largely by cataracts, refractive error, and productivity losses. These results emphasize the need for preventive and treatment strategies and underscore the importance of future cost-benefit and cost-effectiveness analyses to help guide eye health policy in Malta.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.